<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管出版物</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U -NV u8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_source=Chrome&amp;v=2.17.9.post6+86293ac&amp;ff =20230920221424<description>心血管亮点：PubMed 的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_source=Chrome&amp;v=2.17.9.post6+86293ac&amp;ff=20230920221424" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS 源 (2.17.9.post6+86293ac)</generator><language> zh</language><lastbuilddate> 2023 年 9 月 21 日星期四 02:14:29 +0000</lastbuilddate><pubDate> Wed, 20 Sep 2023 06:00:00 -0400</pubDate><ttl> 120</ttl><item><title>心血管成像深度学习：综述</title><link/>https://pubmed.ncbi.nlm.nih.gov/37728933/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230920221424&amp;v=2.17.9.post6+86293ac<description>结论和相关性：深度学习有可能对 CVI 领域产生有意义的影响。深度学习不是一种威胁，而是可以被视为心血管成像仪的合作伙伴，可以减轻技术负担并提高护理效率和质量。高质量的前瞻性证据是仍然需要证明 DL CVI 系统的好处如何大于风险。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol。2023 年 9 月 20 日。doi：10.1001/jamacardio.2023.3142。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">重要性：在深度学习 (DL) 进步的推动下，人工智能 (AI) 有可能重塑心血管成像 (CVI) 领域。虽然用于 CVI 的 DL 仍处于起步阶段，但研究正在加速，以帮助实现这一目标跨多种模式对 CVI 进行处理、处理和/或解释，多种商业产品已投入临床使用。心血管成像仪必须熟悉 DL 系统，包括基本了解其工作原理、与其他自动化系统相比的相对优势本文的目的是以一种简单易懂的方式回顾 DL 到 CVI 的方法和应用，以揭开这一新兴技术的神秘面纱。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">观察：从本质上讲，深度学习只是一系列可调数学运算的应用，将输入数据转换为所需的输出。基于受人类神经系统启发的人工神经网络，有几种类型的深度学习架构适合不同的任务；卷积神经网络特别擅长从 CVI 数据中提取有价值的信息。我们调查了 DL 在 CVI 模式范围内的任务中的一些值得注意的应用。我们还讨论了 DL 系统开发和实施中的挑战，包括避免过度拟合、防止系统偏差、提高可解释性以及促进人机伙伴关系。最后，我们对 CVI 的 DL 未来进行了展望。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论和相关性：深度学习有可能对 CVI 领域产生有意义的影响。深度学习不是一种威胁，而是可以被视为心血管成像仪的合作伙伴，可以减轻技术负担并提高护理效率和质量。高质量的前瞻性证据是仍然需要证明 DL CVI 系统的好处如何大于风险。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37728933/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230920221424&v=2.17.9.post6+86293ac">37728933</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.3142>10.1001/jamacardio.2023.3142</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37728933</guid><pubDate> Wed, 20 Sep 2023 06:00:00 -0400</pubDate><dc:creator>拉姆齐·M·韦贝</dc:creator><dc:creator>阿格洛斯·K·卡萨格洛斯</dc:creator><dc:creator>克里斯蒂安·哈蒙德</dc:creator><dc:creator>河红</dc:creator><dc:creator>法拉兹·艾哈迈德</dc:creator><dc:creator>欧阳大卫</dc:creator><dc:creator>桑吉夫·J·沙阿</dc:creator><dc:creator>帕特里克·M·麦卡锡</dc:creator><dc:creator>詹姆斯·D·托马斯</dc:creator><dc:date>2023-09-20</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>心血管成像深度学习：综述</dc:title><dc:identifier>下午:37728933</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.3142</dc:identifier></item><item><title> β3-肾上腺素能受体激动剂米拉贝隆在结构性心脏病患者中的再利用：Beta3-LVH 2b 期随机临床试验</title><link/>https://pubmed.ncbi.nlm.nih.gov/37728907/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230920221424&amp;v=2.17.9.post6+86293ac<description>结论：在这项研究中，米拉贝隆治疗对没有或轻度心力衰竭症状的结构性心脏病患者的 LV 质量或舒张功能在 12 个月内具有中性影响。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol。2023 年 9 月 20 日。doi：10.1001/jamacardio.2023.3003。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">重要性：左心室 (LV) 肥大会导致心力衰竭 (HF) 的发生和进展，特别是对于心力衰竭前期（B 期）患者，尚未证明任何治疗方法可有效预防向明显心力衰竭（C 期）的转变β3-肾上腺素能受体（β3AR）可能代表一个新靶点，因为它们的激活会减弱左室重塑。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：确定通过重新利用 β3AR 激动剂米拉贝隆来激活 β3AR 是否安全有效，可预防前期或轻度心力衰竭患者左室肥厚和舒张功能障碍的进展。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">设计、环境和参与者：Beta3-LVH 前瞻性、三盲、安慰剂对照 2b 期随机临床试验在 2016 年 9 月 12 日至 2021 年 2 月 26 日期间入组患者，并随访 12 个月。该研究在欧洲 8 个国家（德国、波兰、法国、比利时、意大利、葡萄牙、希腊和英国）的 10 家学术医院进行。年龄 18 岁或以上，有或没有 HF 症状的患者（最大纽约心脏协会 II 级） ）使用超声心动图筛查是否存在左室肥厚（左室质量指数 [LVMI] 增加，女性≥95 g/m2，男性≥115 g/m2）或最大壁厚 13 mm 或更大。进行数据分析2022 年 8 月。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">干预：参与者被随机分配（1:1）服用米拉贝隆（50 mg/d）或安慰剂，根据是否存在心房颤动和/或 2 型糖尿病进行分层，为期 12 个月。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">主要结局和测量：主要终点是 12 个月时使用心脏磁共振成像确定的 LVMI 和左室舒张功能（使用多普勒超声心动图评估舒张早期组织多普勒速度 [E/e&#39;] 比值）。至少有 1 次有效测量的患者任一主要终点均包含在主要分析中。对所有接受至少 1 剂研究药物的患者进行安全性评估。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在筛选的 380 名患者中，有 296 名患者参加了试验。有 147 名患者随机接受米拉贝隆治疗（116 名男性 [79%]；平均 [SD] 年龄，64.0 [10.2] 岁），149 名患者随机接受安慰剂治疗（112 名男性 [79%] 接受安慰剂）。 75%]；平均 [SD] 年龄，62.2 [10.9] 岁）。所有患者均纳入主要意向治疗分析。12 个月时，各组之间的基线和协变量调整差异包括 1.3 g/ m2 LVMI 增加（95% CI，-0.15 至 2.74；P = .08），E/e&#39; 降低 -0.15（95% CI，-0.69 至 0.4；P = .60）。总共 213 项不良反应82 名米拉贝隆治疗患者发生事件（AE）（包括 19 名患者发生 31 起严重 AE），88 名安慰剂治疗患者发生 215 起 AE（包括 22 名患者发生 30 起严重 AE）。试验期间没有发生死亡。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：在这项研究中，米拉贝隆治疗对没有或轻度心力衰竭症状的结构性心脏病患者的 LV 质量或舒张功能在 12 个月内具有中性影响。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">试验注册：ClinicalTrials.gov 标识符：NCT02599480。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37728907/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230920221424&v=2.17.9.post6+86293ac">37728907</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.3003>10.1001/jamacardio.2023.3003</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37728907</guid><pubDate> Wed, 20 Sep 2023 06:00:00 -0400</pubDate><dc:creator>让-吕克·巴利甘</dc:creator><dc:creator>杜尔塞玉米煎饼</dc:creator><dc:creator>瓦娜·布罗斯蒂亚努</dc:creator><dc:creator>芭芭拉·卡萨迪</dc:creator><dc:creator>克里斯托夫·德普瓦</dc:creator><dc:creator>弗兰克·埃德尔曼</dc:creator><dc:creator>凡妮莎·费雷拉</dc:creator><dc:creator>格拉西莫斯·菲利帕托斯</dc:creator><dc:creator>伯恩哈德·格伯</dc:creator><dc:creator>达米安·格鲁森</dc:creator><dc:creator>德克·哈森克莱弗</dc:creator><dc:creator>克里斯蒂安·海伦坎普</dc:creator><dc:creator>伊格内修斯·伊科诺米迪斯</dc:creator><dc:creator>巴托斯·克拉科维亚克</dc:creator><dc:creator>雷诺洛梅尔</dc:creator><dc:creator>马斯利扎·马哈茂德</dc:creator><dc:creator>斯特凡·纽鲍尔</dc:creator><dc:creator>亚历山大·佩尔苏</dc:creator><dc:creator>斯特凡·皮耶尼克</dc:creator><dc:creator>伯克特·皮斯克</dc:creator><dc:creator>伊丽莎白·皮斯克-克雷格</dc:creator><dc:creator>福斯托·平托</dc:creator><dc:creator>彼得·波尼科夫斯基</dc:creator><dc:creator>米歇尔·森尼</dc:creator><dc:creator>让·诺埃尔·特罗胥</dc:creator><dc:creator>南希·范·奥弗斯特拉顿</dc:creator><dc:creator>罗尔夫·瓦赫特</dc:creator><dc:creator>安妮-凯瑟琳·普勒</dc:creator><dc:date>2023-09-20</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>β3-肾上腺素能受体激动剂米拉贝隆在结构性心脏病患者中的再利用：Beta3-LVH 2b 期随机临床试验</dc:title><dc:identifier>下午:37728907</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.3003</dc:identifier></item><item><title> CD1脂质组揭示脂质结合基序和基于大小的抗原展示机制</title><link/>https://pubmed.ncbi.nlm.nih.gov/37725977/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230920221424&amp;v=2.17.9.post6+86293ac<description> CD1 系统结合脂质抗原以展示给 T 细胞。在这里，我们解析了四种人类 CD1 抗原呈递分子的脂质组，提供了自身脂质展示图。回答一个基本问题，检测 >;2,000 个 CD1-脂质复合物展示了自体鞘脂和磷脂的广泛呈现。除了肽抗原经过化学处理外，许多脂质都以未改变的形式呈现。然而，每种类型的 CD1 蛋白都会对自体脂质组进行差异性编辑以... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 9 月 12 日：S0092-8674(23)00912-1. doi: 10.1016/j.cell.2023.08.022. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CD1 系统结合脂质抗原以展示给 T 细胞。在这里，我们解析了四种人类 CD1 抗原呈递分子的脂质组，提供了自身脂质展示图。回答一个基本问题，检测 >;2,000 个 CD1-脂质复合物展示了自鞘脂和磷脂的广泛呈现。除了肽抗原经过化学处理外，许多脂质都以未改变的形式呈现。然而，每种类型的 CD1 蛋白都会对自脂质组进行差异性编辑，以根据脂质长度和化学性质显示不同的捕获基序组成，表明一般的抗原展示机制。对于 CD1a 和 CD1d，脂质大小与 CD1 裂口体积相匹配。CD1c 裂口大小变化更大，CD1b 是异常值，其中配体和裂口显示出极端的尺寸不匹配，这是通过均匀地容纳两个来解释的此外，组成整合 CD1 脂质组的化合物列表支持了脂质阻滞剂和 T 细胞抗原的不断发现。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37725977/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230920221424&v=2.17.9.post6+86293ac">37725977</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.08.022>10.1016/j.cell.2023.08.022</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37725977</guid><pubDate> Tue, 19 Sep 2023 06:00:00 -0400</pubDate><dc:creator>黄守雄</dc:creator><dc:creator>亚当·沙因</dc:creator><dc:creator>郑丹云</dc:creator><dc:creator>陈宜玲</dc:creator><dc:creator>吴秀伟</dc:creator><dc:creator>高瑟姆·R·巴拉吉</dc:creator><dc:creator>雷切尔·法夸尔</dc:creator><dc:creator>斯蒂芬妮·格拉斯</dc:creator><dc:creator>克莱尔·哈德曼</dc:creator><dc:creator>约翰·D·奥特曼</dc:creator><dc:creator>纳比尔·塔希里</dc:creator><dc:creator>阿德里安·J·明纳德</dc:creator><dc:creator>格雷厄姆·S·奥格</dc:creator><dc:creator>雅各布·梅菲尔德</dc:creator><dc:creator>杰米·罗斯约翰</dc:creator><dc:creator>D布兰奇穆迪</dc:creator><dc:date>2023-09-19</dc:date><dc:source>细胞</dc:source><dc:title>CD1脂质组揭示脂质结合基序和基于大小的抗原展示机制</dc:title><dc:identifier>下午:37725977</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.08.022</dc:identifier></item><item><title>主动脉覆膜支架患者危及生命的左房食管瘘并发心房颤动导管消融术</title><link/>https://pubmed.ncbi.nlm.nih.gov/37725918/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230920221424&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Sep 19:ehad609.doi: 10.1093/eurheartj/ehad609. 印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37725918/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230920221424&v=2.17.9.post6+86293ac">37725918</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad609>10.1093/eurheartj/ehad609</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37725918</guid><pubDate> Tue, 19 Sep 2023 06:00:00 -0400</pubDate><dc:creator>田中裕也</dc:creator><dc:creator>黑木健二</dc:creator><dc:creator>加贺茂明</dc:creator><dc:date>2023-09-19</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>主动脉覆膜支架患者危及生命的左房食管瘘并发心房颤动导管消融术</dc:title><dc:identifier>下午:37725918</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad609</dc:identifier></item><item><title>氟喹诺酮类药物与主动脉瘤或夹层之间缺乏关联</title><link/>https://pubmed.ncbi.nlm.nih.gov/37724037/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230920221424&amp;v=2.17.9.post6+86293ac<description>结论：与服用 3GC 的患者相比，口服 FQ 的患者发生 AA/AD 的风险没有显着差异。研究结果表明，当有临床指征时，不应阻止使用 FQ。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Sep 19:ehad627.doi: 10.1093/eurheartj/ehad627. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：据报道，使用氟喹诺酮类药物 (FQ) 会增加主动脉瘤和主动脉夹层 (AA/AD) 的风险。然而，最近的研究表明，不同适应症存在混杂因素。本研究旨在调查与 AA/AD 相关的风险与FQ一起使用。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：这项全国性的基于人群的研究包括 2005 年至 2016 年门诊期间接受口服 FQ 或第三代头孢菌素 (3GC) 处方的年龄≥20 岁的成年人。数据来源是国家健康保险服务报销数据库。结果是住院或院内死亡，初步诊断为 AA/AD。使用自我对照病例系列 (SCCS) 和 Cox 比例风险模型。自我对照病例系列比较了风险期内主要结局的发生率与控制期相比。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：共纳入 954 308 名患者（777 109 名使用 FQ 的患者和 177 199 名使用 3GC 的患者）。3GC 组风险期和风险前期之间 AA/AD 的发生率比较高[11.000；11.000]。 95% 置信区间 (CI) 1.420-85.200] 与 FQ 组 (2.000; 95% CI 0.970-4.124) 相比。接受 FQ 和 3GC 的患者中 AA/AD 的总体发生率分别为每 10 万人 5.40 例和 8.47 例治疗加权Cox比例风险模型的逆概率两组之间的风险无显着差异（调整后风险比0.752；95% CI 0.515-1.100），亚组和敏感性分析结果一致。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：与服用 3GC 的患者相比，口服 FQ 的患者发生 AA/AD 的风险没有显着差异。研究结果表明，当有临床指征时，不应阻止使用 FQ。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37724037/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230920221424&v=2.17.9.post6+86293ac">37724037</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad627>10.1093/eurheartj/ehad627</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37724037</guid><pubDate> Tue, 19 Sep 2023 06:00:00 -0400</pubDate><dc:creator>许庆民</dc:creator><dc:creator>康敏孙</dc:creator><dc:creator>郑在勋</dc:creator><dc:date>2023-09-19</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>氟喹诺酮类药物与主动脉瘤或夹层之间缺乏关联</dc:title><dc:identifier>下午：37724037</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad627</dc:identifier></item><item><title>根据年龄和遗传倾向的获得性危险因素和房颤事件</title><link/>https://pubmed.ncbi.nlm.nih.gov/37723974/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230920221424&amp;v=2.17.9.post6+86293ac<description>结论：这项研究提供了英国成年人队列中与年龄和遗传易感性相关的房颤危险因素的全面信息。根据年龄和遗传风险分层对风险因素进行优先排序可能有助于实现精确有效的房颤预防。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Sep 19:ehad615.doi: 10.1093/eurheartj/ehad615. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景与目的：心房颤动（AF）是成人中最常见的持续性心律失常，根据年龄和遗传风险组对房颤危险因素进行调查对于促进房颤预防和控制的个体化策略至关重要。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：来自英国生物银行队列的总共 409 661 名参与者（平均年龄 56 岁；46% 为男性）在基线时没有 AF，并且拥有有关危险因素的完整信息。危险比和人群归因风险 (PAR)研究人员检查了 3 个年龄组（40-49 岁、50-59 岁）与 23 种风险因素相关的 AF 事件百分比，包括 3 种社会因素、7 种健康行为、6 种心脏代谢因素、6 种临床合并症和遗传风险评分 (GRS) 、60-69 岁）和 3 个遗传风险群体（低、中、高 GRS）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：经过 5 027 587 人年的随访，23 847 名参与者出现了 AF。大多数心脏代谢因素和临床合并症与年龄存在显着的相互作用，其中这种关联在年轻群体中普遍增强（Pinteraction &lt; .002）。然而，只有低 LDL 胆固醇、肾功能不全和心血管疾病与遗传风险存在显着的交互作用，并且在较低遗传风险群体中，这些因素的关联性更强 (Pinteraction &lt; .002)。心脏代谢因素始终占最大数量。所有年龄组（PAR：36.2%-38.9%）和遗传风险组（34.0%-41.9%）的房颤病例发生率，其中高血压和超重/肥胖是两个主要的可改变因素。健康行为（PAR：11.5% vs. 40-49岁组中房颤病例的发生率（8.7%）和遗传危险因素（19.1% vs. 14.3%）比60-69岁组中的房颤病例多，而临床合并症的影响在不同年龄组中保持相对稳定。归因于总体心脏代谢因素的房颤风险（PAR：低遗传风险组为 41.9%，高遗传风险组为 34.0%）和临床合并症（24.7% 和 15.9%）随着遗传风险的增加而降低。 社会因素的影响从年龄和遗传风险来看，各组的房颤发生率相对较低。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：这项研究提供了英国成年人队列中与年龄和遗传易感性相关的房颤危险因素的全面信息。根据年龄和遗传风险分层对风险因素进行优先排序可能有助于实现精确有效的房颤预防。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37723974/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230920221424&v=2.17.9.post6+86293ac">37723974</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad615>10.1093/eurheartj/ehad615</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37723974</guid><pubDate> Tue, 19 Sep 2023 06:00:00 -0400</pubDate><dc:creator>王宁建</dc:creator><dc:creator>余跃峰</dc:creator><dc:creator>孙英</dc:creator><dc:creator>张浩杰</dc:creator><dc:creator>王玉英</dc:creator><dc:creator>陈驰</dc:creator><dc:creator>小谭</dc:creator><dc:creator>王斌</dc:creator><dc:creator>英利路</dc:creator><dc:date>2023-09-19</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>根据年龄和遗传倾向的获得性危险因素和房颤事件</dc:title><dc:identifier>下午:37723974</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad615</dc:identifier></item><item><title>肺动脉高压相关的动态左心室流出道梗阻</title><link/>https://pubmed.ncbi.nlm.nih.gov/37723925/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230920221424&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Sep 19:ehad605.doi: 10.1093/eurheartj/ehad605. 印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37723925/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230920221424&v=2.17.9.post6+86293ac">37723925</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad605>10.1093/eurheartj/ehad605</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37723925</guid><pubDate> Tue, 19 Sep 2023 06:00:00 -0400</pubDate><dc:creator>刘嘉妮</dc:creator><dc:creator>赵振刚</dc:creator><dc:creator>罗凤鸣</dc:creator><dc:date>2023-09-19</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>肺动脉高压相关的动态左心室流出道梗阻</dc:title><dc:identifier>下午:37723925</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad605</dc:identifier></item><item><title>双胎妊娠急性主动脉夹层快速急救</title><link/>https://pubmed.ncbi.nlm.nih.gov/37723880/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230920221424&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Sep 19:ehad601.doi: 10.1093/eurheartj/ehad601. 印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37723880/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230920221424&v=2.17.9.post6+86293ac">37723880</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad601>10.1093/eurheartj/ehad601</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37723880</guid><pubDate> Tue, 19 Sep 2023 06:00:00 -0400</pubDate><dc:creator>唐雪梅</dc:creator><dc:creator>吴晓晓</dc:creator><dc:creator>王一平</dc:creator><dc:date>2023-09-19</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>双胎妊娠急性主动脉夹层快速急救</dc:title><dc:identifier>下午：37723880</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad601</dc:identifier></item><item><title>免疫球蛋白G4相关疾病的冠状动脉表现</title><link/>https://pubmed.ncbi.nlm.nih.gov/37723867/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230920221424&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Sep 19:ehad610.doi: 10.1093/eurheartj/ehad610. 印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37723867/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230920221424&v=2.17.9.post6+86293ac">37723867</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad610>10.1093/eurheartj/ehad610</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37723867</guid><pubDate> Tue, 19 Sep 2023 06:00:00 -0400</pubDate><dc:creator>平谷大吾</dc:creator><dc:creator>渡部弘明</dc:creator><dc:creator>星智也</dc:creator><dc:date>2023-09-19</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>免疫球蛋白G4相关疾病的冠状动脉表现</dc:title><dc:identifier>下午:37723867</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad610</dc:identifier></item><item><title>偏头痛和心血管疾病：机制和方法挑战</title><link/>https://pubmed.ncbi.nlm.nih.gov/37723319/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230920221424&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Nat Rev Cardiol。2023 年 9 月 18 日。doi：10.1038/s41569-023-00934-7。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37723319/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230920221424&v=2.17.9.post6+86293ac">37723319</a> | DOI： <a href=https://doi.org/10.1038/s41569-023-00934-7>10.1038/s41569-023-00934-7</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37723319</guid><pubDate> Mon, 18 Sep 2023 06:00:00 -0400</pubDate><dc:creator>托比亚斯·库尔特</dc:creator><dc:creator>帕梅拉·M·瑞斯特</dc:creator><dc:date>2023-09-18</dc:date><dc:source> 《自然》评论、心脏病学</dc:source><dc:title>偏头痛和心血管疾病：机制和方法挑战</dc:title><dc:identifier>下午:37723319</dc:identifier><dc:identifier> doi:10.1038/s41569-023-00934-7</dc:identifier></item><item><title>基于消融的节律控制在心房颤动和心力衰竭的错综复杂的网络中的作用</title><link/>https://pubmed.ncbi.nlm.nih.gov/37721977/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230920221424&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 9 月 19 日；148(12):933-935. doi: 10.1161/CIRCULATIONAHA.123.065329. Epub 2023 年 9 月 18 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37721977/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230920221424&v=2.17.9.post6+86293ac">37721977</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065329>10.1161/CIRCULATIONAHA.123.065329</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37721977</guid><pubDate> Mon, 18 Sep 2023 06:00:00 -0400</pubDate><dc:creator>拉蒂卡·帕卡什</dc:creator><dc:creator>艾琳·奥米拉</dc:creator><dc:creator>安东尼·SL·唐</dc:creator><dc:date>2023-09-18</dc:date><dc:source>循环</dc:source><dc:title>基于消融的节律控制在心房颤动和心力衰竭的错综复杂的网络中的作用</dc:title><dc:identifier>下午：37721977</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.065329</dc:identifier></item><item><title> Figliozzi 等人关于文章“MIDA-Q 死亡率风险评分：二尖瓣脱垂谱的定量预后工具”的信函</title><link/>https://pubmed.ncbi.nlm.nih.gov/37721976/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230920221424&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 9 月 19 日；148(12):978-979. doi: 10.1161/CIRCULATIONAHA.123.064780. Epub 2023 年 9 月 18 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37721976/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230920221424&v=2.17.9.post6+86293ac">37721976</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064780>10.1161 / CIRCULATIONAHA.123.064780</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37721976</guid><pubDate> Mon, 18 Sep 2023 06:00:00 -0400</pubDate><dc:creator>斯特凡诺·菲廖齐</dc:creator><dc:creator>乔治斯·乔治普洛斯</dc:creator><dc:creator>皮尔-乔治·马西</dc:creator><dc:date>2023-09-18</dc:date><dc:source>循环</dc:source><dc:title>Figliozzi 等人关于文章“MIDA-Q 死亡率风险评分：二尖瓣脱垂谱的定量预后工具”的信函</dc:title><dc:identifier>下午:37721976</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.064780</dc:identifier></item><item><title> Essayagh 等人对有关文章“MIDA-Q 死亡率风险评分：二尖瓣脱垂谱的定量预后工具”的回复</title><link/>https://pubmed.ncbi.nlm.nih.gov/37721975/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230920221424&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 9 月 19 日；148(12):980-981. doi: 10.1161/CIRCULATIONAHA.123.065630. Epub 2023 年 9 月 18 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37721975/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230920221424&v=2.17.9.post6+86293ac">37721975</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065630>10.1161/CIRCULATIONAHA.123.065630</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37721975</guid><pubDate> Mon, 18 Sep 2023 06:00:00 -0400</pubDate><dc:creator>本杰明·埃萨亚</dc:creator><dc:creator>乔瓦尼·本法里</dc:creator><dc:creator>克莱门斯·安托万</dc:creator><dc:creator>弗朗西斯科·格里吉奥尼</dc:creator><dc:creator>蒂埃里·勒图尔诺</dc:creator><dc:creator>让·克里斯蒂安·鲁塞尔</dc:creator><dc:creator>杰伦·J·巴克斯</dc:creator><dc:creator>尼娜·阿杰蒙·马桑</dc:creator><dc:creator>阿尼克·范·韦恩加登</dc:creator><dc:creator>克里斯托夫·特里布依洛</dc:creator><dc:creator>丹·鲁斯纳鲁</dc:creator><dc:creator>阿维拉姆·霍赫施塔特</dc:creator><dc:creator>严·托皮尔斯基</dc:creator><dc:creator>普拉宾·塔帕</dc:creator><dc:creator>赫克托一世·米凯莱娜</dc:creator><dc:creator>莫里斯·恩里克斯·萨拉诺</dc:creator><dc:date>2023-09-18</dc:date><dc:source>循环</dc:source><dc:title>Essayagh 等人对有关文章“MIDA-Q 死亡率风险评分：二尖瓣脱垂谱的定量预后工具”的回复</dc:title><dc:identifier>下午：37721975</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.065630</dc:identifier></item><item><title> SNRK 通过肌动蛋白解聚介导心脏肥大中的 DNA 损伤和核形态变化</title><link/>https://pubmed.ncbi.nlm.nih.gov/37721051/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230920221424&amp;v=2.17.9.post6+86293ac<description>结论：这些结果表明，SNRK 通过与 DSTN 相互作用而在心脏肥大和 DNA 损伤中发挥关键作用。这种相互作用微调肌动蛋白聚合，以减少 DDR 并维持适当的心肌细胞核形状和形态。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 9 月 18 日。doi：10.1161/CIRCULATIONAHA.123.066002。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：适当的核组织对于心肌细胞功能至关重要，因为核形态和染色质结构的整体结构重塑是心血管疾病发生和进展的基础。之前的报道暗示 DNA 损伤在心脏肥大中发挥作用；然而，这一过程的机制尚不清楚。AMPK（AMP 激活蛋白激酶）蛋白质家族调节新陈代谢和 DNA 损伤反应 (DDR)。在这里，我们检查该家族的成员 SNRK（SNF1 相关激酶）是否在心脏代谢，还通过 DDR 和细胞核结构特性的变化参与肥厚重塑。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们对心脏特异性的<i>Snrk</i> <sup>-/-</sup>小鼠进行经主动脉结扎，以评估其对心脏功能和 DDR 的影响。同时，我们在体外调节 SNRK 并评估其对 DDR 和核参数的影响。我们还使用磷酸蛋白质组学来鉴定新的最后，使用免疫共沉淀来验证 Destrin (DSTN) 作为 SNRK 的结合伴侣，调节其对细胞核和 DDR 的影响。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：心脏特异性<i>Snrk</i> <sup>-/-</sup>小鼠因经主动脉结扎而表现出较差的心功能和心脏肥大，并且其心脏中 DDR 标记 pH2AX（磷酸组蛋白 2AX）增加。此外，体外<i>Snrk</i>敲低导致心肌肥厚增加。 DNA 损伤和染色质压缩，以及核平坦度和 3 维体积的改变。磷酸化蛋白质组学研究发现了一个新的 SNRK 靶点 DSTN，它是 F-肌动蛋白解聚因子蛋白的成员，可直接结合并解聚 F-肌动蛋白。SNRK 结合通过 SNRK 敲低，除了细胞肥大之外，DSTN 和 DSTN 下调还可以逆转过度的 DNA 损伤和核参数的变化。我们还证明 SNRK 敲低会促进肌动蛋白过度解聚，这是通过 G-肌动蛋白与 F-肌动蛋白的比率增加来衡量的。最后，jasplakinolide 是一种 F-肌动蛋白的药理稳定剂，可挽救 SNRK 下调细胞中增加的 DNA 损伤和异常的核形态。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：这些结果表明，SNRK 通过与 DSTN 相互作用而在心脏肥大和 DNA 损伤中发挥关键作用。这种相互作用微调肌动蛋白聚合，以减少 DDR 并维持适当的心肌细胞核形状和形态。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37721051/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230920221424&v=2.17.9.post6+86293ac">37721051</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066002>10.1161/CIRCULATIONAHA.123.066002</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37721051</guid><pubDate> Mon, 18 Sep 2023 06:00:00 -0400</pubDate><dc:creator>宝琳娜·斯坦奇克</dc:creator><dc:creator>立越由纪</dc:creator><dc:creator>贾森·夏皮罗</dc:creator><dc:creator>克里西卡·纳尤杜</dc:creator><dc:creator>陈一涵</dc:creator><dc:creator>扎卡里·齐伯</dc:creator><dc:creator>马修·席普玛</dc:creator><dc:creator>亚当·德赫苏斯</dc:creator><dc:creator>阿米尔·马哈茂德扎德</dc:creator><dc:creator>阿什利·阿克拉米</dc:creator><dc:creator>张向春</dc:creator><dc:creator>侯赛因·阿德哈里</dc:creator><dc:date>2023-09-18</dc:date><dc:source>循环</dc:source><dc:title>SNRK 通过肌动蛋白解聚介导心脏肥大中的 DNA 损伤和核形态变化</dc:title><dc:identifier>下午：37721051</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.066002</dc:identifier></item><item><title>患有先天性心脏病的儿童和青少年的心理健康状况：一项基于丹麦人群的队列研究</title><link/>https://pubmed.ncbi.nlm.nih.gov/37721036/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230920221424&amp;v=2.17.9.post6+86293ac<description>结论：超过三分之一的先天性心脏病儿童在 18 岁时就因心理健康问题被诊断或接受治疗。心理健康问题在生命早期就开始出现，在患有严重或单心室心脏病的男性和儿童中最为突出。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 9 月 18 日。doi：10.1161/CIRCULATIONAHA.123.064705。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：尽管已知先天性心脏病（CHD）儿童的心理健康负担，但由于缺乏比较队列和基于人群的随访数据，文献受到限制。我们检查了先天性心脏病（CHD）儿童的心理健康状况的发生率，相对于 3 个队列的比较。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：这项基于人群的队列研究通过跨国家登记处的个人数据链接，确定了 1996 年至 2017 年丹麦所有患有 CHD 的儿童（&lt;18 岁；n = 16 473）。这使得能够进行完整的随访比较队列包括一般人群的儿童 (n=162 204)、患有 CHD 的儿童的兄弟姐妹 (n=20 079) 以及患有非 CHD 重大先天性异常的儿童 (n=47 799)。 心理健康状况使用住院和门诊出院代码、处方数据以及基于社区的心理学、精神病学和心理治疗服务的使用数据来确定。我们使用以下方法计算了 18 岁的累积发病率、发病率和调整后的风险比 (aHR) Cox 回归。aHR 考虑了性别、CHD 诊断年份、父母心理健康状况和社会经济状况。所有估计值均按年龄、性别和 CHD 复杂性进行分层。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：CHD 队列中 18 岁时心理健康状况的累积发生率为 35.1%（95% CI，34.0%-36.1%），对应 aHR 为 1.64（95% CI，1.58-1.71）、1.41（与普通人群、兄弟姐妹和主要先天性异常人群相比，分别为 95% CI (1.30-1.52) 和 1.02 (95% CI, 0.98-1.07)。心理健康发病率在儿童早期和青春期表现出明显的峰值。相对于女性和轻度或中度 CHD 儿童，重度或单心室 CHD 儿童的精神健康状况发生率更高。与一般人群和兄弟姐妹队列相比，CHD 队列中的发病率和 aHR 最高严重应激反应、注意力缺陷/多动障碍、智力障碍、自闭症谱系障碍。与重大先天异常队列的儿童相比，aHR接近1。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：超过三分之一的先天性心脏病儿童在 18 岁时就因心理健康问题被诊断或接受治疗。心理健康问题在生命早期就开始出现，在患有严重或单心室心脏病的男性和儿童中最为突出。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37721036/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230920221424&v=2.17.9.post6+86293ac">37721036</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064705>10.1161/循环AHA.123.064705</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37721036</guid><pubDate> Mon, 18 Sep 2023 06:00:00 -0400</pubDate><dc:creator>金伯利·G·迈尔斯</dc:creator><dc:creator>多拉·科曼丁·法卡斯</dc:creator><dc:creator>克里斯蒂娜·劳格森</dc:creator><dc:creator>亨里克·托夫特·索伦森</dc:creator><dc:creator>纳丁·卡斯帕里安</dc:creator><dc:creator>尼古拉斯·马德森</dc:creator><dc:date>2023-09-18</dc:date><dc:source>循环</dc:source><dc:title>患有先天性心脏病的儿童和青少年的心理健康状况：一项基于丹麦人群的队列研究</dc:title><dc:identifier>下午：37721036</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.064705</dc:identifier></item><item><title> 2023 年美国心脏协会重点更新因中毒导致心脏骤停或危及生命的中毒患者的管理：美国心脏协会心肺复苏和紧急心血管护理指南更新</title><link/>https://pubmed.ncbi.nlm.nih.gov/37721023/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230920221424&amp;v=2.17.9.post6+86293ac<description>在这次重点更新中，美国心脏协会为因中毒而导致心脏骤停、呼吸骤停和难治性休克的患者的复苏提供了最新指南。基于结构化证据审查，为苯二氮卓类、β-肾上腺素能受体拮抗剂（又称β受体阻滞剂）、L型钙通道拮抗剂（俗称钙通道阻滞剂）、可卡因、氰化物、地高辛及相关... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 9 月 18 日。doi：10.1161/CIR.0000000000001161。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> In this focused update, the American Heart Association provides updated guidance for resuscitation of patients with cardiac arrest, respiratory arrest, and refractory shock due to poisoning. Based on structured evidence reviews, guidelines are provided for the treatment of critical poisoning from benzodiazepines, β-adrenergic receptor antagonists (also known as β-blockers), L-type calcium channel antagonists (commonly called calcium channel blockers), cocaine, cyanide, digoxin and related cardiac glycosides, local anesthetics, methemoglobinemia, opioids, organophosphates and carbamates, sodium channel antagonists (also called sodium channel blockers), and sympathomimetics. Recommendations are also provided for the use of venoarterial extracorporeal membrane oxygenation. These guidelines discuss the role of atropine, benzodiazepines, calcium, digoxin-specific immune antibody fragments, electrical pacing, flumazenil, glucagon, hemodialysis, hydroxocobalamin, hyperbaric oxygen, insulin, intravenous lipid emulsion, lidocaine, methylene blue, naloxone, pralidoxime, sodium bicarbonate, sodium nitrite, sodium thiosulfate, vasodilators, and vasopressors for the management of specific critical poisonings.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37721023/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230920221424&v=2.17.9.post6+86293ac">37721023</a> | DOI: <a href=https://doi.org/10.1161/CIR.0000000000001161>10.1161/CIR.0000000000001161</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37721023</guid><pubDate> Mon, 18 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Eric J Lavonas</dc:creator><dc:creator> Peter D Akpunonu</dc:creator><dc:creator> Ann M Arens</dc:creator><dc:creator> Kavita M Babu</dc:creator><dc:creator> Dazhe Cao</dc:creator><dc:creator> Robert S Hoffman</dc:creator><dc:creator> Christopher O Hoyte</dc:creator><dc:creator> Maryann E Mazer-Amirshahi</dc:creator><dc:creator> Andrew Stolbach</dc:creator><dc:creator> Maude St-Onge</dc:creator><dc:creator> Trevonne M Thompson</dc:creator><dc:creator> George Sam Wang</dc:creator><dc:creator> Amber V Hoover</dc:creator><dc:creator> Ian R Drennan</dc:creator><dc:creator> American Heart Association</dc:creator><dc:date> 2023-09-18</dc:date><dc:source> Circulation</dc:source><dc:title> 2023 American Heart Association Focused Update on the Management of Patients With Cardiac Arrest or Life-Threatening Toxicity Due to Poisoning: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care</dc:title><dc:identifier> pmid:37721023</dc:identifier><dc:identifier> doi:10.1161/CIR.0000000000001161</dc:identifier></item><item><title> Oncogenic Role of THOR, a Conserved Cancer/Testis Long Non-coding RNA</title><link/> https://pubmed.ncbi.nlm.nih.gov/37714137/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230920221424&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 Sep 14;186(19):4254-4255. doi: 10.1016/j.cell.2023.08.025.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37714137/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230920221424&v=2.17.9.post6+86293ac">37714137</a> | DOI: <a href=https://doi.org/10.1016/j.cell.2023.08.025>10.1016/j.cell.2023.08.025</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37714137</guid><pubDate> Fri, 15 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Yasuyuki Hosono</dc:creator><dc:creator> Yashar S Niknafs</dc:creator><dc:creator> John R Prensner</dc:creator><dc:creator> Matthew K Iyer</dc:creator><dc:creator> Saravana M Dhanasekaran</dc:creator><dc:creator> Rohit Mehra</dc:creator><dc:creator> Sethuramasundaram Pitchiaya</dc:creator><dc:creator> Jean Tien</dc:creator><dc:creator> June Escara-Wilke</dc:creator><dc:creator> Anton Poliakov</dc:creator><dc:creator> Shih-Chun Chu</dc:creator><dc:creator> Sahal Saleh</dc:creator><dc:creator> Keerthana Sankar</dc:creator><dc:creator> Fengyun Su</dc:creator><dc:creator> Shuling Guo</dc:creator><dc:creator> Yuanyuan Qiao</dc:creator><dc:creator> Susan M Freier</dc:creator><dc:creator> Huynh-Hoa Bui</dc:creator><dc:creator> Xuhong Cao</dc:creator><dc:creator> Rohit Malik</dc:creator><dc:creator> Timothy M Johnson</dc:creator><dc:creator> David G Beer</dc:creator><dc:creator> Felix Y Feng</dc:creator><dc:creator> Weibin Zhou</dc:creator><dc:creator> Arul M Chinnaiyan</dc:creator><dc:date> 2023-09-15</dc:date><dc:source> Cell</dc:source><dc:title> Oncogenic Role of THOR, a Conserved Cancer/Testis Long Non-coding RNA</dc:title><dc:identifier> pmid:37714137</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.08.025</dc:identifier></item><item><title> Orphan quality control shapes network dynamics and gene expression</title><link/> https://pubmed.ncbi.nlm.nih.gov/37714136/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230920221424&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 Sep 14;186(19):4252-4253. doi: 10.1016/j.cell.2023.08.006.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37714136/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230920221424&v=2.17.9.post6+86293ac">37714136</a> | DOI: <a href=https://doi.org/10.1016/j.cell.2023.08.006>10.1016/j.cell.2023.08.006</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37714136</guid><pubDate> Fri, 15 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Kevin G Mark</dc:creator><dc:creator> SriDurgaDevi Kolla</dc:creator><dc:creator> Jacob D Aguirre</dc:creator><dc:creator> Danielle M Garshott</dc:creator><dc:creator> Stefan Schmitt</dc:creator><dc:creator> Diane L Haakonsen</dc:creator><dc:creator> Christina Xu</dc:creator><dc:creator> Lukas Kater</dc:creator><dc:creator> Georg Kempf</dc:creator><dc:creator> Brenda Martínez-González</dc:creator><dc:creator> David Akopian</dc:creator><dc:creator> Stephanie K See</dc:creator><dc:creator> Nicolas H Thomä</dc:creator><dc:creator> Michael Rapé</dc:creator><dc:date> 2023-09-15</dc:date><dc:source> Cell</dc:source><dc:title> Orphan quality control shapes network dynamics and gene expression</dc:title><dc:identifier> pmid:37714136</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.08.006</dc:identifier></item><item><title> Modular pooled discovery of synthetic knockin sequences to program durable cell therapies</title><link/> https://pubmed.ncbi.nlm.nih.gov/37714135/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230920221424&amp;v=2.17.9.post6+86293ac<description> Chronic stimulation can cause T cell dysfunction and limit the efficacy of cellular immunotherapies. Improved methods are required to compare large numbers of synthetic knockin (KI) sequences to reprogram cell functions. Here, we developed modular pooled KI screening (ModPoKI), an adaptable platform for modular construction of DNA KI libraries using barcoded multicistronic adaptors. We built two ModPoKI libraries of 100 transcription factors (TFs) and 129 natural and synthetic surface receptors... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 Sep 14;186(19):4216-4234.e33. doi: 10.1016/j.cell.2023.08.013.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Chronic stimulation can cause T cell dysfunction and limit the efficacy of cellular immunotherapies. Improved methods are required to compare large numbers of synthetic knockin (KI) sequences to reprogram cell functions. Here, we developed modular pooled KI screening (ModPoKI), an adaptable platform for modular construction of DNA KI libraries using barcoded multicistronic adaptors. We built two ModPoKI libraries of 100 transcription factors (TFs) and 129 natural and synthetic surface receptors (SRs). Over 30 ModPoKI screens across human TCR- and CAR-T cells in diverse conditions identified a transcription factor AP4 (TFAP4) construct that enhanced fitness of chronically stimulated CAR-T cells and anti-cancer function in vitro and in vivo. ModPoKI&#39;s modularity allowed us to generate an ∼10,000-member library of TF combinations. Non-viral KI of a combined BATF-TFAP4 polycistronic construct enhanced fitness. Overexpressed BATF and TFAP4 co-occupy and regulate key gene targets to reprogram T cell function. ModPoKI facilitates the discovery of complex gene constructs to program cellular functions.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37714135/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230920221424&v=2.17.9.post6+86293ac">37714135</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC10508323/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230920221424&v=2.17.9.post6+86293ac">PMC10508323</a> | DOI: <a href=https://doi.org/10.1016/j.cell.2023.08.013>10.1016/j.cell.2023.08.013</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37714135</guid><pubDate> Fri, 15 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Franziska Blaeschke</dc:creator><dc:creator> Yan Yi Chen</dc:creator><dc:creator> Ryan Apathy</dc:creator><dc:creator> Bence Daniel</dc:creator><dc:creator> Andy Y Chen</dc:creator><dc:creator> Peixin Amy Chen</dc:creator><dc:creator> Katalin Sandor</dc:creator><dc:creator> Wenxi Zhang</dc:creator><dc:creator> Zhongmei Li</dc:creator><dc:creator> Cody T Mowery</dc:creator><dc:creator> Tori N Yamamoto</dc:creator><dc:creator> William A Nyberg</dc:creator><dc:creator> Angela To</dc:creator><dc:creator> Ruby Yu</dc:creator><dc:creator> Raymund Bueno</dc:creator><dc:creator> Min Cheol Kim</dc:creator><dc:creator> Ralf Schmidt</dc:creator><dc:creator> Daniel B Goodman</dc:creator><dc:creator> Tobias Feuchtinger</dc:creator><dc:creator> Justin Eyquem</dc:creator><dc:creator> Chun Jimmie Ye</dc:creator><dc:creator> Julia Carnevale</dc:creator><dc:creator> Ansuman T Satpathy</dc:creator><dc:creator> Eric Shifrut</dc:creator><dc:creator> Theodore L Roth</dc:creator><dc:creator> Alexander Marson</dc:creator><dc:date> 2023-09-15</dc:date><dc:source> Cell</dc:source><dc:title> Modular pooled discovery of synthetic knockin sequences to program durable cell therapies</dc:title><dc:identifier> pmid:37714135</dc:identifier><dc:identifier> pmc:PMC10508323</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.08.013</dc:identifier></item><item><title> Complex effects of sequence variants on lipid levels and coronary artery disease</title><link/> https://pubmed.ncbi.nlm.nih.gov/37714134/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230920221424&amp;v=2.17.9.post6+86293ac<description> Many sequence variants have additive effects on blood lipid levels and, through that, on the risk of coronary artery disease (CAD). We show that variants also have non-additive effects and interact to affect lipid levels as well as affecting variance and correlations. Variance and correlation effects are often signatures of epistasis or gene-environmental interactions. These complex effects can translate into CAD risk. For example, Trp154Ter in FUT2 protects against CAD among subjects with the... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 Sep 14;186(19):4085-4099.e15. doi: 10.1016/j.cell.2023.08.012.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Many sequence variants have additive effects on blood lipid levels and, through that, on the risk of coronary artery disease (CAD). We show that variants also have non-additive effects and interact to affect lipid levels as well as affecting variance and correlations. Variance and correlation effects are often signatures of epistasis or gene-environmental interactions. These complex effects can translate into CAD risk. For example, Trp154Ter in FUT2 protects against CAD among subjects with the A1 blood group, whereas it associates with greater risk of CAD in others. His48Arg in ADH1B interacts with alcohol consumption to affect lipid levels and CAD. The effect of variants in TM6SF2 on blood lipids is greatest among those who never eat oily fish but absent from those who often do. This work demonstrates that variants that affect variance of quantitative traits can allow for the discovery of epistasis and interactions of variants with the environment.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37714134/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230920221424&v=2.17.9.post6+86293ac">37714134</a> | DOI: <a href=https://doi.org/10.1016/j.cell.2023.08.012>10.1016/j.cell.2023.08.012</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37714134</guid><pubDate> Fri, 15 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Audunn S Snaebjarnarson</dc:creator><dc:creator> Anna Helgadottir</dc:creator><dc:creator> Gudny A Arnadottir</dc:creator><dc:creator> Erna V Ivarsdottir</dc:creator><dc:creator> Gudmar Thorleifsson</dc:creator><dc:creator> Egil Ferkingstad</dc:creator><dc:creator> Gudmundur Einarsson</dc:creator><dc:creator> Gardar Sveinbjornsson</dc:creator><dc:creator> Thorgeir E Thorgeirsson</dc:creator><dc:creator> Magnus O Ulfarsson</dc:creator><dc:creator> Bjarni V Halldorsson</dc:creator><dc:creator> Isleifur Olafsson</dc:creator><dc:creator> Christian Erikstrup</dc:creator><dc:creator> Ole B Pedersen</dc:creator><dc:creator> Mette Nyegaard</dc:creator><dc:creator> Mie T Bruun</dc:creator><dc:creator> Henrik Ullum</dc:creator><dc:creator> Søren Brunak</dc:creator><dc:creator> Kasper Karmark Iversen</dc:creator><dc:creator> Alex Hoerby Christensen</dc:creator><dc:creator> Morten S Olesen</dc:creator><dc:creator> Jonas Ghouse</dc:creator><dc:creator> Karina Banasik</dc:creator><dc:creator> DBDS Genomic Consortium</dc:creator><dc:creator> Kirk U Knowlton</dc:creator><dc:creator> David O Arnar</dc:creator><dc:creator> Gudmundur Thorgeirsson</dc:creator><dc:creator> Lincoln Nadauld</dc:creator><dc:creator> Sisse Rye Ostrowski</dc:creator><dc:creator> Henning Bundgaard</dc:creator><dc:creator> Hilma Holm</dc:creator><dc:creator> Patrick Sulem</dc:creator><dc:creator> Kari Stefansson</dc:creator><dc:creator> Daniel F Gudbjartsson</dc:creator><dc:date> 2023-09-15</dc:date><dc:source> Cell</dc:source><dc:title> Complex effects of sequence variants on lipid levels and coronary artery disease</dc:title><dc:identifier> pmid:37714134</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.08.012</dc:identifier></item><item><title> TGF-β signaling in health and disease</title><link/> https://pubmed.ncbi.nlm.nih.gov/37714133/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230920221424&amp;v=2.17.9.post6+86293ac<description> The TGF-β regulatory system plays crucial roles in the preservation of organismal integrity. TGF-β signaling controls metazoan embryo development, tissue homeostasis, and injury repair through coordinated effects on cell proliferation, phenotypic plasticity, migration, metabolic adaptation, and immune surveillance of multiple cell types in shared ecosystems. Defects of TGF-β signaling, particularly in epithelial cells, tissue fibroblasts, and immune cells, disrupt immune tolerance, promote... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 Sep 14;186(19):4007-4037. doi: 10.1016/j.cell.2023.07.036.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> The TGF-β regulatory system plays crucial roles in the preservation of organismal integrity. TGF-β signaling controls metazoan embryo development, tissue homeostasis, and injury repair through coordinated effects on cell proliferation, phenotypic plasticity, migration, metabolic adaptation, and immune surveillance of multiple cell types in shared ecosystems. Defects of TGF-β signaling, particularly in epithelial cells, tissue fibroblasts, and immune cells, disrupt immune tolerance, promote inflammation, underlie the pathogenesis of fibrosis and cancer, and contribute to the resistance of these diseases to treatment. Here, we review how TGF-β coordinates multicellular response programs in health and disease and how this knowledge can be leveraged to develop treatments for diseases of the TGF-β system.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37714133/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230920221424&v=2.17.9.post6+86293ac">37714133</a> | DOI: <a href=https://doi.org/10.1016/j.cell.2023.07.036>10.1016/j.cell.2023.07.036</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37714133</guid><pubDate> Fri, 15 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Joan Massagué</dc:creator><dc:creator> Dean Sheppard</dc:creator><dc:date> 2023-09-15</dc:date><dc:source> Cell</dc:source><dc:title> TGF-β signaling in health and disease</dc:title><dc:identifier> pmid:37714133</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.07.036</dc:identifier></item></channel></rss>